Treatment with a long-acting injectable antipsychotic combined with cognitive training significantly improved cognitive deficits in patients after a first episode of schizophrenia, according to a study published online in Psychological Medicine.
A majority of inpatients with schizophrenia who were treated with electroconvulsive therapy (ECT) demonstrated clinical improvement, irrespective of whether they were capable of consenting before psychiatric treatment, a study found.
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
A large-scale analysis of insurance databases found a high prevalence of medical and psychiatric comorbidities among patients with schizophrenia, compared with matched controls, according to a poster presented at Psych Congress 2020.
HP-3070, the asenapine transdermal system, has a more predictable absorption profile and lower peak-to-trough fluctuations than sublingual asenapine, according to a poster presented at Psych Congress 2020.
Sustained use of the antipsychotic olanzapine in patients with remitted psychotic depression was associated with a thinning of the cortex, when compared with placebo, according to a study published online in JAMA Psychiatry.